Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial
Go back to Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial| Regeneron (NASDAQ: REGN) | Delayed: 618.03 +5.53 (0.90%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $612.50 | 52 Week High | $592.36 | |||
| Open | $607.92 | 52 Week Low | $325.35 | |||
| Day High | $621.79 | P/E | 162.21 | |||
| Day Low | $607.92 | EPS | $3.81 | |||
| Volume | 1,279,853 | |||||
